Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Climb 3.9% – Here’s Why

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares shot up 3.9% on Wednesday. The stock traded as high as $14.98 and last traded at $15.0270. 458,654 shares traded hands during mid-day trading, a decline of 84% from the average daily volume of 2,784,684 shares. The stock had previously closed at $14.46.

Trending Headlines about Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Ultragenyx agreed to sell a Rare Pediatric Disease Priority Review Voucher for $210 million. The voucher was awarded after the FDA approved GENGLYCOS (DTX401), a treatment for glycogen storage disease type Ia. The proceeds provide substantial cash without issuing new shares and can support development of the company’s rare-disease therapies. Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
• Positive Sentiment: The transaction monetizes a valuable regulatory asset and improves Ultragenyx’s financial flexibility. Investors may view the cash infusion as helpful while the company funds commercial activities and its pipeline of treatments for rare diseases. Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash
• Positive Sentiment: The European Medicines Agency validated Ultragenyx’s submission for its Sanfilippo syndrome type A (MPS IIIA) gene therapy. Validation confirms the application can proceed through the formal review process, representing progress toward a potential European approval and expanding the company’s long-term pipeline opportunity. Ultragenyx EMA Validation of MPS IIIA Gene Therapy
• Neutral Sentiment: The EMA validation is not an approval, and the gene therapy still faces a substantive regulatory review. In addition, the $210 million PRV proceeds are a one-time gain rather than recurring product revenue, so investors will continue to focus on clinical execution and commercialization.

Analysts Set New Price Targets

Several research firms recently issued reports on RARE. Guggenheim decreased their target price on shares of Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating on the stock in a research report on Tuesday, August 4th. Canaccord Genuity Group increased their price target on shares of Ultragenyx Pharmaceutical from $37.00 to $39.00 and gave the stock a “buy” rating in a research note on Friday, September 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ultragenyx Pharmaceutical in a research note on Tuesday. Jefferies Financial Group decreased their price target on shares of Ultragenyx Pharmaceutical from $77.00 to $28.00 and set a “buy” rating on the stock in a report on Thursday, September 3rd. Finally, William Blair raised shares of Ultragenyx Pharmaceutical to a “hold” rating in a research note on Wednesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Ultragenyx Pharmaceutical presently has a consensus rating of “Hold” and an average price target of $34.58.

Ultragenyx Pharmaceutical Price Performance

The business has a fifty day moving average of $20.06 and a 200 day moving average of $23.78. The stock has a market cap of $1.51 billion, a PE ratio of -2.62 and a beta of 0.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) EPS for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.32. The firm had revenue of $214.00 million during the quarter, compared to analyst estimates of $183.08 million. During the same quarter last year, the business posted ($1.17) earnings per share. The firm’s revenue for the quarter was up 28.5% on a year-over-year basis. On average, equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -3.96 EPS for the current year.

Institutional Trading of Ultragenyx Pharmaceutical

A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in shares of Ultragenyx Pharmaceutical during the second quarter valued at $355,746,000. Assenagon Asset Management S.A. boosted its stake in Ultragenyx Pharmaceutical by 1,030.4% in the 1st quarter. Assenagon Asset Management S.A. now owns 2,257,671 shares of the biopharmaceutical company’s stock worth $47,298,000 after purchasing an additional 2,057,951 shares during the period. Bank of America Corp DE acquired a new stake in Ultragenyx Pharmaceutical during the 2nd quarter valued at $38,347,000. GW&K Investment Management LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 19.6% in the fourth quarter. GW&K Investment Management LLC now owns 1,375,407 shares of the biopharmaceutical company’s stock valued at $31,634,000 after purchasing an additional 225,238 shares in the last quarter. Finally, Jefferies Financial Group Inc. purchased a new stake in shares of Ultragenyx Pharmaceutical in the second quarter valued at $31,040,000. 97.67% of the stock is owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic diseases. The company targets conditions with limited or no treatment options, including metabolic disorders, skeletal diseases and other inherited conditions. Its work includes the development of medicines, biologic therapies and gene therapy candidates intended to address the underlying causes or significant symptoms of these disorders.

Ultragenyx’s commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Dojolvi (triheptanoin), a medical food used to manage long-chain fatty acid oxidation disorders; and Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII.